ScreenerHero

VALN Valneva SE

NAS · US · Healthcare · Biotechnology · valneva.com
5.870USD+0.17%Mkt Cap: 556.61M $P/E: —

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap556.61M USD
Enterprise Value644.37M USD
Revenue (TTM)142.94M USD
Gross Profit67.52M USD
Net Income (TTM)-115.19M USD
Revenue/Share1.60 USD
Last Price5.870 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees620
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)4.92
PEG—
EV/EBITDA-6.53
EV/Revenue4.51
P/S3.89
P/B5.89
EPS (TTM)-2.10
EPS (Forward)1.19
52W Range
4.75015% of range12.23
52W High12.23 USD
52W Low4.750 USD
Profitability
Gross Margin38.66%
Oper. Margin-74.92%
EBITDA Margin-69.07%
Profit Margin-65.95%
ROE-108.50%
ROA-28.88%
Growth
Revenue Growth-27.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.89M USD
CapEx (TTM)4.48M USD
FCF Margin-29.73%
FCF Yield-7.64%
Net Debt88.71M USD
Net Debt/EBITDA-0.90
Balance Sheet
Debt/Equity1.95
Current Ratio2.16
Quick Ratio1.33
Book Value/Sh0.99 USD
Cash/Share1.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.25 USD
Upside (mean)+108.7%
Target Range5.000 USD – 18.00 USD
5.000+108.7% to mean18.00
# Analysts4
Ownership
Shares Out.94.82M
Float85.68M
Insiders0.00%
Institutions3.99%
Short Interest
Short Ratio4.5d
Short % Float0.20%
Short % Out.0.20%
Shares Short191.76K
Short (prev mo.)160.47K
Technical
SMA 506.199 (-5.3%)
SMA 2007.142 (-17.8%)
Beta1.26
S&P 52W Chg15.78%
Avg Vol (30d)34.14K
Avg Vol (10d)27.63K
Technical Indicators
RSI (14)40.6
MACD-0.1195
MACD Signal-0.0187
MACD Hist.-0.1008
BB Upper7.079 USD
BB Middle6.341 USD
BB Lower5.604 USD
BB Width23.26%
ATR (14)0.2425 USD
Vol Ratio (20d)0.51x